The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...